Slide 1Welcome to Jeopardy! New Drugs of 2012 Brand/ Generic Indication Whats New? Potpourri Mechanism Slide 2 200 400 600 800 1000 200 400 600 800 1000 200 400 600 800 1000…

Slide 1XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps… Slide 2 Countries with XDR-TB Confirmed cases to date Czech Republic The boundaries…

1.ANTIBIOTIC RESISTANCE THREATS in the United States, 2013 2. TABLE OF CONTENTS Foreword...............................................................................................…

1. Title Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis The New England Journal of Medicine 367;16 nejm.1508 org october 18, 2012 Guide: Dr. Akhil…

Introduction . . . . . . . . . . .146 Gastrointestinal . . . . . . . .147 Dermatologic and Hypersensitivity . . . . . . . .151 Hematologic Abnormalities . . . . . . . . .…

Slide 1 Slide 2 CORPORATE OVERVIEW TNIB is a late stage immunotherapy company with short term sustainable revenue delivering low cost, effective, safe immuno therapies treatments…

Slide 1 ANTIMICROBIAL THERAPY CHAPTER 13 Copyright © 2012 John Wiley & Sons, Inc. All rights reserved. Slide 2 Mad cow disease is caused by an “infectious” protein…

Mycobacterial Infections Robert F. Nash D.O. 2007 Mycobacterial Infections M. tuberculosis M. avium complex M. kansasii M. fortuitum M. chelonae/abscessus M. smegmatis History…

A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting A decentralized model of care for drug-resistant tuberculosis in a high HIV…

Tuberculosis Infection Control Tuberculosis Infection Control Dr AW Dreyer Clinical Microbiologist Centre for tuberculosis (incorporating NTBRL) National Institute for Communicable…